LA JOLLA, Calif., Dec. 6, 2016 /PRNewswire/ -- Regulus
Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company
leading the discovery and development of innovative medicines
targeting microRNAs, today announced two new drug development
candidates at its R&D day, held in New York. The first candidate, RGLS5040, is an
anti-miR targeting microRNA-27 (miR-27) for the treatment of
cholestatic diseases. The second candidate, RGLS4326, is an
anti-miR targeting microRNA-17 (miR-17) for the treatment of
autosomal dominant polycystic kidney disease (ADPKD).
"We are delighted to announce the addition of two new drug
candidates to our growing portfolio of potential microRNA
therapeutics. We believe both RGLS5040 and RGLS4326 have very
favorable preclinical profiles with the potential to fulfill
meaningful unmet medical needs," said Paul C Grint, M.D.,
President and Chief Executive Officer of Regulus. "We are
currently conducting IND-enabling work and finalizing development
plans for RG5040 and RGLS4326 and expect to file INDs for both drug
candidates in the second half of 2017. Today's announcement of two
new drug development candidates underlines the confidence we have
in our rigorous targeting and validation process, which we believe
should enable us to identify at least one new drug development
candidate per year moving forward."
For additional details on Regulus' two new drug development
candidates as well as other information detailed at Regulus'
R&D day, please visit the investor relations section of
Regulus' website www.regulusrx.com where a replay of the webcast
presentation is available for a limited time.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical
company leading the discovery and development of innovative
medicines targeting microRNAs. Regulus has leveraged its
oligonucleotide drug discovery and development expertise to develop
a well-balanced microRNA therapeutics pipeline complemented by a
maturing microMarkersSM biomarkers platform and a rich
intellectual property estate to retain its leadership in the
microRNA field. Regulus is developing RG-101, a
GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment
of chronic hepatitis C virus infection, and RG-012, an anti-miR
targeting microRNA-21 for the treatment of Alport syndrome, a
life-threatening kidney disease driven by genetic mutations with no
approved therapy. In addition, RG-125, a GalNAc-conjugated
anti-miR targeting microRNA-103/107 for the treatment of NASH in
patients with type 2 diabetes/pre-diabetes, has entered Phase I/IIa
clinical development through its strategic alliance with
AstraZeneca. Regulus is also advancing several programs
toward clinical development in renal, hepatic and central nervous
systems diseases. Regulus' commitment to innovation has resulted in
multiple peer-reviewed publications in notable scientific journals
and has resulted in the formation of strategic alliances with
AstraZeneca and Sanofi. Regulus maintains its corporate
headquarters in La Jolla,
CA. For more information, please visit
http://www.regulusrx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements associated with the expected ability
of Regulus to undertake certain activities and accomplish certain,
the projected timeline of clinical development activities, and
expectations regarding future therapeutic and commercial potential
of Regulus' business plans, technologies and intellectual property
related to microRNA therapeutics and biomarkers being discovered
and developed by Regulus. Because such statements are subject
to risks and uncertainties, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Words such as "believes," "anticipates," "plans," "expects,"
"intends," "will," "goal," "potential" and similar expressions are
intended to identify forward-looking statements. These
forward-looking statements are based upon Regulus' current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results and the timing of
events could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, risks associated
with the process of discovering, developing and commercializing
drugs that are safe and effective for use as human therapeutics,
and in the endeavor of building a business around such drugs.
These and other risks concerning Regulus' financial position and
programs are described in additional detail in Regulus filings with
the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Regulus undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were
made.
Logo - http://photos.prnewswire.com/prnh/20160519/370141LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/regulus-announces-new-drug-development-candidates-300373935.html
SOURCE Regulus Therapeutics Inc.